Swedish Vaccines Biz, Biotech Enter $6M Takeover Agreement
Investor Karolinska Development AB said Friday its portfolio vaccines business has entered into a reverse takeover agreement, worth approximately 55 million Swedish kronor ($6 million), with Stockholm-based biotechnology company Novakand....To view the full article, register now.
Already a subscriber? Click here to view full article